BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 16633046)

  • 1. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
    Morales A; Salguti S; Miao CL; Lewis JD
    Inflamm Bowel Dis; 2007 Apr; 13(4):380-5. PubMed ID: 17206711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
    Cuffari C; Dassopoulos T; Turnbough L; Thompson RE; Bayless TM
    Clin Gastroenterol Hepatol; 2004 May; 2(5):410-7. PubMed ID: 15118980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
    Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?
    Heerasing NM; Ng JF; Dowling D
    Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
    Hanai H; Iida T; Takeuchi K; Arai O; Watanabe F; Abe J; Maruyama Y; Oohata A; Ikeya K; Kageoka M; Miwa I; Yoshirou S; Hosoda Y; Kubota T
    Inflamm Bowel Dis; 2010 Aug; 16(8):1376-81. PubMed ID: 20049951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
    Poon SS; Asher R; Jackson R; Kneebone A; Collins P; Probert C; Dibb M; Subramanian S
    J Crohns Colitis; 2015 Aug; 9(8):640-6. PubMed ID: 25968584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
    Uchiyama K; Takagi T; Iwamoto Y; Kondo N; Okayama T; Yoshida N; Kamada K; Katada K; Handa O; Ishikawa T; Yasuda H; Sakagami J; Konishi H; Yagi N; Naito Y; Itoh Y
    PLoS One; 2014; 9(4):e95080. PubMed ID: 24762746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.
    Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
    Inflamm Bowel Dis; 2015 May; 21(5):1054-62. PubMed ID: 25851563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites].
    Alvarez Beltran M; Infante Pina D; Tormo Carnicé R; Segarra Cantón O; Redecillas Ferreiro S
    An Pediatr (Barc); 2009 Feb; 70(2):126-31. PubMed ID: 19217567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
    Dubinsky MC; Yang H; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
    Gastroenterology; 2002 Apr; 122(4):904-15. PubMed ID: 11910342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.